{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T00:52:59Z","timestamp":1791593579620,"version":"4.3.4"},"reference-count":172,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,11,27]],"date-time":"2019-11-27T00:00:00Z","timestamp":1574812800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000864","name":"Michael J. Fox Foundation for Parkinson's Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000864","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001671","name":"Hereditary Disease Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001671","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005725","name":"CHDI Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005725","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neurobiology of Disease"],"published-print":{"date-parts":[[2020,2]]},"DOI":"10.1016\/j.nbd.2019.104619","type":"journal-article","created":{"date-parts":[[2019,10,25]],"date-time":"2019-10-25T11:48:29Z","timestamp":1572004109000},"page":"104619","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":95,"special_numbering":"C","title":["Optimizing intracellular antibodies (intrabodies\/nanobodies) to treat neurodegenerative disorders"],"prefix":"10.1016","volume":"134","author":[{"given":"Anne","family":"Messer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David C.","family":"Butler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.nbd.2019.104619_bb0005","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.1107\/S1744309110042168","article-title":"Crystallization and preliminary X-ray diffraction analysis of a specific VHH domain against mouse prion protein","volume":"66","author":"Abskharon","year":"2010","journal-title":"Acta Crystallogr. Sect. F Struct. Biol. Cryst. Commun."},{"key":"10.1016\/j.nbd.2019.104619_bb0010","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1021\/ja407527p","article-title":"Probing the N-terminal \u03b2-sheet conversion in the crystal structure of the human prion protein bound to a Nanobody","volume":"136","author":"Abskharon","year":"2014","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.nbd.2019.104619_bb0015","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1126\/science.1087348","article-title":"Games played by rogue proteins in Prion disorders and Alzheimer\u2019s disease","volume":"302","author":"Aguzzi","year":"2003","journal-title":"Science"},{"key":"10.1016\/j.nbd.2019.104619_bb0020","doi-asserted-by":"crossref","first-page":"29427","DOI":"10.1074\/jbc.M109.013193","article-title":"Phosphorylation of threonine 3: implications for Huntingtin aggregation and neurotoxicity","volume":"284","author":"Aiken","year":"2009","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.nbd.2019.104619_bb0025","first-page":"10","article-title":"An Intrabody drug (rAAV6-INT41) reduces the binding of N-terminal Huntingtin fragment(s) to DNA to basal levels in PC12 cells and delays cognitive loss in the R6\/2 animal model","volume":"2016","author":"Amaro","year":"2016","journal-title":"J. Neurodegener. Dis."},{"key":"10.1016\/j.nbd.2019.104619_bb0030","first-page":"879","article-title":"Aggregation of alpha-synuclein in Lewy bodies of sporadic Parkinson's disease and dementia with Lewy bodies","volume":"152","author":"Baba","year":"1998","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.nbd.2019.104619_bb0035","doi-asserted-by":"crossref","DOI":"10.1038\/nrdp.2015.5","article-title":"Huntington disease","volume":"1","author":"Bates","year":"2015","journal-title":"Nat. Rev. Dis. Primers"},{"key":"10.1016\/j.nbd.2019.104619_bb0040","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1038\/nbt.1608","article-title":"Harnessing chaperone-mediated autophagy for the selective degradation of mutant huntingtin protein","volume":"28","author":"Bauer","year":"2010","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.nbd.2019.104619_bb0045","first-page":"581","article-title":"Can intrabodies serve as neuroprotective therapies for Parkinson's disease? Beginning thoughts","volume":"3","author":"Bhatt","year":"2013","journal-title":"J. Park. Dis."},{"key":"10.1016\/j.nbd.2019.104619_bb0050","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.nbd.2010.04.007","article-title":"Cystamine and intrabody co-treatment confers additional benefits in a fly model of Huntington's disease","volume":"40","author":"Bortvedt","year":"2010","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.nbd.2019.104619_bb0055","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0029199","article-title":"Bifunctional anti-huntingtin proteasome-directed intrabodies mediate efficient degradation of mutant huntingtin exon 1 protein fragments","volume":"6","author":"Butler","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.nbd.2019.104619_bb0060","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.pneurobio.2011.11.004","article-title":"Engineered antibody therapies to counteract mutant huntingtin and related toxic intracellular proteins","volume":"97","author":"Butler","year":"2012","journal-title":"Prog. Neurobiol."},{"key":"10.1016\/j.nbd.2019.104619_bb0065","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1093\/protein\/gzu041","article-title":"Differential nuclear localization of complexes may underlie in vivo intrabody efficacy in Huntington's disease","volume":"27","author":"Butler","year":"2014","journal-title":"Protein Eng. Des. Sel."},{"key":"10.1016\/j.nbd.2019.104619_bb0070","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0165964","article-title":"Bifunctional anti-non-amyloid component alpha-Synuclein Nanobodies are protective in situ","volume":"11","author":"Butler","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.nbd.2019.104619_bb0075","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.molmed.2008.07.004","article-title":"The potential of intracellular antibodies for therapeutic targeting of protein-misfolding diseases","volume":"14","author":"Cardinale","year":"2008","journal-title":"Trends Mol. Med."},{"key":"10.1016\/j.nbd.2019.104619_bb0080","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1074\/jbc.M407360200","article-title":"Trapping prion protein in the endoplasmic reticulum impairs PrPC maturation and prevents PrPSc accumulation","volume":"280","author":"Cardinale","year":"2005","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.nbd.2019.104619_bb0085","first-page":"2638","article-title":"A new means of inducibly inactivating a cellular protein","volume":"8","author":"Carlson","year":"1988","journal-title":"Mol. Cell. Biol."},{"key":"10.1016\/j.nbd.2019.104619_bb0090","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1038\/nrn1806","article-title":"Normal huntingtin function: an alternative approach to Huntington's disease","volume":"6","author":"Cattaneo","year":"2005","journal-title":"Nat. Rev. Neurosci."},{"key":"10.1016\/j.nbd.2019.104619_bb0095","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1038\/s41596-018-0097-3","article-title":"Systemic AAV vectors for widespread and targeted gene delivery in rodents","volume":"14","author":"Challis","year":"2019","journal-title":"Nat. Protoc."},{"key":"10.1016\/j.nbd.2019.104619_bb0100","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0304-3940(00)01247-7","article-title":"Alpha-synuclein immunoreactivity of huntingtin polyglutamine aggregates in striatum and cortex of Huntington's disease patients and transgenic mouse models","volume":"289","author":"Charles","year":"2000","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.nbd.2019.104619_bb0105","doi-asserted-by":"crossref","DOI":"10.1016\/j.nbd.2019.104587","article-title":"Immunotherapy in Parkinson's disease: current status and future directions","volume":"132","author":"Chatterjee","year":"2019","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.nbd.2019.104619_bb0110","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1038\/s41531-018-0062-4","article-title":"Proteasome-targeted nanobodies alleviate pathology and functional decline in an alpha-synuclein-based Parkinson's disease model","volume":"4","author":"Chatterjee","year":"2018","journal-title":"NPJ Parkinsons Dis."},{"key":"10.1016\/j.nbd.2019.104619_bb0115","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1111\/j.1749-6632.2009.05229.x","article-title":"Lewy body pathology in fetal grafts","volume":"1184","author":"Chu","year":"2010","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"10.1016\/j.nbd.2019.104619_bb0120","doi-asserted-by":"crossref","first-page":"17616","DOI":"10.1073\/pnas.0408134101","article-title":"Potent inhibition of huntingtin aggregation and cytotoxicity by a disulfide bond-free single-domain intracellular antibody","volume":"101","author":"Colby","year":"2004","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.nbd.2019.104619_bb0125","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1016\/j.jmb.2004.07.054","article-title":"Development of a human light chain variable domain (V(L)) intracellular antibody specific for the amino terminus of huntingtin via yeast surface display","volume":"342","author":"Colby","year":"2004","journal-title":"J. Mol. Biol."},{"key":"10.1016\/j.nbd.2019.104619_bb0130","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1093\/hmg\/ddr477","article-title":"Alpha-Synuclein levels modulate Huntington's disease in mice","volume":"21","author":"Corrochano","year":"2012","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.nbd.2019.104619_bb0135","first-page":"251426","article-title":"Protein tau: prime cause of synaptic and neuronal degeneration in Alzheimer's disease","volume":"2012","author":"Crespo-Biel","year":"2012","journal-title":"Int. J. Alzheimers Dis."},{"key":"10.1016\/j.nbd.2019.104619_bb0140","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/j.neuron.2010.12.035","article-title":"Huntington's disease: can mice lead the way to treatment?","volume":"69","author":"Crook","year":"2011","journal-title":"Neuron"},{"key":"10.1016\/j.nbd.2019.104619_bb0145","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1038\/cr.2013.153","article-title":"Chaperone-mediated autophagy: roles in disease and aging","volume":"24","author":"Cuervo","year":"2014","journal-title":"Cell Res."},{"key":"10.1016\/j.nbd.2019.104619_bb0150","doi-asserted-by":"crossref","first-page":"1907","DOI":"10.1016\/j.bbapap.2014.08.016","article-title":"Antibodies and protein misfolding: from structural research tools to therapeutic strategies","volume":"1844","author":"De Genst","year":"2014","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.nbd.2019.104619_bb0155","doi-asserted-by":"crossref","first-page":"2166","DOI":"10.1016\/j.jmb.2015.03.021","article-title":"Structure of a single-chain Fv bound to the 17 N-terminal residues of huntingtin provides insights into pathogenic amyloid formation and suppression","volume":"427","author":"De Genst","year":"2015","journal-title":"J. Mol. Biol."},{"key":"10.1016\/j.nbd.2019.104619_bb0160","doi-asserted-by":"crossref","first-page":"412","DOI":"10.2174\/1567205013666160930110551","article-title":"Targeting tumor necrosis factor alpha for Alzheimer's disease","volume":"14","author":"Decourt","year":"2017","journal-title":"Curr. Alzheimer Res."},{"key":"10.1016\/j.nbd.2019.104619_bb0165","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1002\/mds.26370","article-title":"Alpha-synuclein propagation: new insights from animal models","volume":"31","author":"Dehay","year":"2016","journal-title":"Mov. Disord."},{"key":"10.1016\/j.nbd.2019.104619_bb0170","doi-asserted-by":"crossref","DOI":"10.1016\/j.nbd.2019.104569","article-title":"Antibody-based therapies for Huntington's disease: current status and future directions","volume":"132","author":"Denis","year":"2019","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.nbd.2019.104619_bb0175","doi-asserted-by":"crossref","first-page":"12887","DOI":"10.1523\/JNEUROSCI.2107-13.2013","article-title":"Antisense reduction of tau in adult mice protects against seizures","volume":"33","author":"DeVos","year":"2013","journal-title":"J. Neurosci."},{"key":"10.1016\/j.nbd.2019.104619_bb0180","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aag0481","article-title":"Tau reduction prevents neuronal loss and reverses pathological tau deposition and seeding in mice with tauopathy","volume":"9","author":"DeVos","year":"2017","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.nbd.2019.104619_bb0185","doi-asserted-by":"crossref","first-page":"2194","DOI":"10.1093\/brain\/awy117","article-title":"Tau reduction in the presence of amyloid-beta prevents tau pathology and neuronal death in vivo","volume":"141","author":"DeVos","year":"2018","journal-title":"Brain"},{"key":"10.1016\/j.nbd.2019.104619_bb0190","article-title":"Conformational dynamics of tau in the cell quantified by an intramolecular FRET biosensor in physiological and pathological context","author":"Di Primio","year":"2016","journal-title":"bioRxiv"},{"key":"10.1016\/j.nbd.2019.104619_bb0195","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.nbd.2017.05.002","article-title":"Differential effects of immunotherapy with antibodies targeting alpha-synuclein oligomers and fibrils in a transgenic model of synucleinopathy","volume":"104","author":"El-Agnaf","year":"2017","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.nbd.2019.104619_bb0200","doi-asserted-by":"crossref","first-page":"2393","DOI":"10.1016\/j.jmb.2013.03.031","article-title":"The mysterious C-terminal tail of alpha-synuclein: nanobody's guess","volume":"425","author":"Eliezer","year":"2013","journal-title":"J. Mol. Biol."},{"key":"10.1016\/j.nbd.2019.104619_bb0205","doi-asserted-by":"crossref","first-page":"3116","DOI":"10.1021\/acs.biochem.6b00149","article-title":"Structural effects of two Camelid Nanobodies directed to distinct C-terminal epitopes on alpha-Synuclein","volume":"55","author":"El-Turk","year":"2016","journal-title":"Biochemistry"},{"key":"10.1016\/j.nbd.2019.104619_bb0210","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1016\/j.jmb.2007.02.089","article-title":"Isolation of a human single chain antibody fragment against oligomeric alpha-synuclein that inhibits aggregation and prevents alpha-synuclein-induced toxicity","volume":"368","author":"Emadi","year":"2007","journal-title":"J. Mol. Biol."},{"key":"10.1016\/j.nbd.2019.104619_bb0215","doi-asserted-by":"crossref","first-page":"11048","DOI":"10.1074\/jbc.M806559200","article-title":"Detecting morphologically distinct oligomeric forms of alpha-synuclein","volume":"284","author":"Emadi","year":"2009","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.nbd.2019.104619_bb0220","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.bbamcr.2013.05.008","article-title":"Ubiquitin-independent proteasomal degradation","volume":"1843","author":"Erales","year":"2014","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.nbd.2019.104619_bb0225","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1007\/978-1-4939-7825-0_6","article-title":"Mouse models of Huntington's disease","volume":"1780","author":"Farshim","year":"2018","journal-title":"Methods Mol. Biol."},{"issue":"3","key":"10.1016\/j.nbd.2019.104619_bb0230","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1042\/bj3460577","article-title":"Alpha-synuclein overexpression promotes aggregation of mutant huntingtin","volume":"346","author":"Furlong","year":"2000","journal-title":"J. Biochem."},{"key":"10.1016\/j.nbd.2019.104619_bb0235","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.antiviral.2010.08.001","article-title":"Inhibition of protease-inhibitor-resistant hepatitis C virus replicons and infectious virus by intracellular intrabodies","volume":"88","author":"Gal-Tanamy","year":"2010","journal-title":"Antivir. Res."},{"key":"10.1016\/j.nbd.2019.104619_bb0240","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.nbd.2013.04.007","article-title":"Single chain variable fragment antibodies block aggregation and toxicity induced by familial ALS-linked mutant forms of SOD1","volume":"56","author":"Ghadge","year":"2013","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.nbd.2019.104619_bb0245","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.nbd.2018.08.021","article-title":"Single chain variable fragment antibodies directed against SOD1 ameliorate disease in mutant SOD1 transgenic mice","volume":"121","author":"Ghadge","year":"2019","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.nbd.2019.104619_bb0250","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1126\/science.2928784","article-title":"Prevention of rapid intracellular degradation of ODC by a carboxyl-terminal truncation","volume":"243","author":"Ghoda","year":"1989","journal-title":"Science"},{"key":"10.1016\/j.nbd.2019.104619_bb0255","doi-asserted-by":"crossref","first-page":"11823","DOI":"10.1016\/S0021-9258(19)38472-8","article-title":"Trypanosome ornithine decarboxylase is stable because it lacks sequences found in the carboxyl terminus of the mouse enzyme which target the latter for intracellular degradation","volume":"265","author":"Ghoda","year":"1990","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.nbd.2019.104619_bb0260","doi-asserted-by":"crossref","first-page":"2380","DOI":"10.1074\/jbc.M008919200","article-title":"A hydrophobic stretch of 12 amino acid residues in the middle of alpha-synuclein is essential for filament assembly","volume":"276","author":"Giasson","year":"2001","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.nbd.2019.104619_bb0265","doi-asserted-by":"crossref","DOI":"10.1126\/science.1255555","article-title":"Alzheimer's and Parkinson's diseases: the prion concept in relation to assembled A\u03b2, tau, and \u03b1-synuclein","volume":"349","author":"Goedert","year":"2015","journal-title":"Science"},{"key":"10.1016\/j.nbd.2019.104619_bb0270","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/s13041-017-0298-7","article-title":"Propagation of tau aggregates","volume":"10","author":"Goedert","year":"2017","journal-title":"Mol. Brain"},{"key":"10.1016\/j.nbd.2019.104619_bb0275","doi-asserted-by":"crossref","first-page":"6182","DOI":"10.1523\/JNEUROSCI.0857-08.2008","article-title":"Full-length human mutant huntingtin with a stable polyglutamine repeat can elicit progressive and selective neuropathogenesis in BACHD mice","volume":"28","author":"Gray","year":"2008","journal-title":"J. Neurosci."},{"key":"10.1016\/j.nbd.2019.104619_bb0280","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1016\/j.neuron.2009.11.020","article-title":"Serines 13 and 16 are critical determinants of full-length human mutant huntingtin induced disease pathogenesis in HD mice","volume":"64","author":"Gu","year":"2009","journal-title":"Neuron"},{"key":"10.1016\/j.nbd.2019.104619_bb0285","doi-asserted-by":"crossref","first-page":"2397","DOI":"10.1016\/j.jmb.2013.01.040","article-title":"Nanobodies raised against monomeric alpha-synuclein distinguish between fibrils at different maturation stages","volume":"425","author":"Guilliams","year":"2013","journal-title":"J. Mol. Biol."},{"key":"10.1016\/j.nbd.2019.104619_bb0290","doi-asserted-by":"crossref","first-page":"9982","DOI":"10.1074\/jbc.M111.305417","article-title":"Protein misfolding detected early in pathogenesis of transgenic mouse model of Huntington disease using amyloid seeding assay","volume":"287","author":"Gupta","year":"2012","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.nbd.2019.104619_bb0295","doi-asserted-by":"crossref","first-page":"19232","DOI":"10.1073\/pnas.0703793104","article-title":"Directed selection of a conformational antibody domain that prevents mature amyloid fibril formation by stabilizing Abeta protofibrils","volume":"104","author":"Habicht","year":"2007","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.nbd.2019.104619_bb0300","doi-asserted-by":"crossref","first-page":"17085","DOI":"10.1038\/nrdp.2017.85","article-title":"Amyotrophic lateral sclerosis","volume":"3","author":"Hardiman","year":"2017","journal-title":"Nat. Rev. Dis. Prim."},{"key":"10.1016\/j.nbd.2019.104619_bb0305","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.nbd.2010.08.017","article-title":"Nicotinamide improves motor deficits and upregulates PGC-1alpha and BDNF gene expression in a mouse model of Huntington's disease","volume":"41","author":"Hathorn","year":"2011","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.nbd.2019.104619_bb0310","doi-asserted-by":"crossref","first-page":"7420","DOI":"10.1007\/s12035-019-1597-z","article-title":"Bispecific antibody fragment targeting APP and inducing alpha-site cleavage restores neuronal health in an Alzheimer's mouse model","volume":"56","author":"He","year":"2019","journal-title":"Mol. Neurobiol."},{"key":"10.1016\/j.nbd.2019.104619_bb0315","doi-asserted-by":"crossref","first-page":"17495","DOI":"10.1074\/jbc.M110.212027","article-title":"Dependence of proteasome processing rate on substrate unfolding","volume":"286","author":"Henderson","year":"2011","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.nbd.2019.104619_bb0320","article-title":"Delivering genes across the blood-brain barrier: LY6A, a novel cellular receptor for AAV-PHP.B capsids","author":"Huang","year":"2019","journal-title":"bioRxiv"},{"key":"10.1016\/j.nbd.2019.104619_bb0325","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.neuron.2019.03.020","article-title":"Therapeutic AAV gene transfer to the nervous system: a clinical reality","volume":"102","author":"Hudry","year":"2019","journal-title":"Neuron"},{"key":"10.1016\/j.nbd.2019.104619_bb0330","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/S0065-3233(08)60493-3","article-title":"Antibody binding sites","volume":"49","author":"Huston","year":"1996","journal-title":"Adv. Protein Chem."},{"key":"10.1016\/j.nbd.2019.104619_bb0335","doi-asserted-by":"crossref","first-page":"122","DOI":"10.14802\/jmd.15033","article-title":"Genetics of progressive Supranuclear palsy","volume":"8","author":"Im","year":"2015","journal-title":"J. Mov. Disord."},{"key":"10.1016\/j.nbd.2019.104619_bb0340","doi-asserted-by":"crossref","first-page":"408","DOI":"10.3389\/fnins.2016.00408","article-title":"Alpha-synuclein oligomers-neurotoxic molecules in Parkinson's disease and other Lewy body disorders","volume":"10","author":"Ingelsson","year":"2016","journal-title":"Front. Neurosci."},{"key":"10.1016\/j.nbd.2019.104619_bb0345","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1038\/369761a0","article-title":"Three-dimensional structure of \u03b2-galactosidase from E. coli","volume":"369","author":"Jacobson","year":"1994","journal-title":"Nature"},{"key":"10.1016\/j.nbd.2019.104619_bb0350","doi-asserted-by":"crossref","first-page":"686","DOI":"10.4161\/mabs.21696","article-title":"Fusion to a highly charged proteasomal retargeting sequence increases soluble cytoplasmic expression and efficacy of diverse anti-synuclein intrabodies","volume":"4","author":"Joshi","year":"2012","journal-title":"MAbs"},{"key":"10.1016\/j.nbd.2019.104619_bb0355","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/S0306-4522(00)00077-4","article-title":"Enhanced vulnerability to oxidative stress by alpha-synuclein mutations and C-terminal truncation","volume":"97","author":"Kanda","year":"2000","journal-title":"Neuroscience"},{"key":"10.1016\/j.nbd.2019.104619_bb0360","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1074\/jbc.M507753200","article-title":"Inducible expression of tau repeat domain in cell models of tauopathy: aggregation is toxic to cells but can be reversed by inhibitor drugs","volume":"281","author":"Khlistunova","year":"2006","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.nbd.2019.104619_bb0365","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1073\/pnas.022631799","article-title":"Effects of intracellular expression of anti-huntingtin antibodies of various specificities on mutant huntingtin aggregation and toxicity","volume":"99","author":"Khoshnan","year":"2002","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.nbd.2019.104619_bb0370","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/S0361-9230(01)00599-8","article-title":"New anti-huntingtin monoclonal antibodies: implications for huntingtin conformation and its binding proteins","volume":"56","author":"Ko","year":"2001","journal-title":"Brain Res Bull."},{"key":"10.1016\/j.nbd.2019.104619_bb0375","article-title":"Structure and pathology of tau protein in Alzheimer disease","volume":"2012","author":"Kolarova","year":"2012","journal-title":"Int. J. Alzheimers Dis."},{"key":"10.1016\/j.nbd.2019.104619_bb0380","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/j.expneurol.2009.09.016","article-title":"Propagation of host disease to grafted neurons: accumulating evidence","volume":"220","author":"Kordower","year":"2009","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.nbd.2019.104619_bb0385","doi-asserted-by":"crossref","first-page":"1798","DOI":"10.1002\/mds.26879","article-title":"Mechanisms for cell-to-cell propagation no longer lag behind","volume":"31","author":"Kordower","year":"2016","journal-title":"Mov. Disord."},{"key":"10.1016\/j.nbd.2019.104619_bb0390","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0005727","article-title":"Conformational targeting of fibrillar polyglutamine proteins in live cells escalates aggregation and cytotoxicity","volume":"4","author":"Kvam","year":"2009","journal-title":"PLoS One"},{"key":"10.1016\/j.nbd.2019.104619_bb0395","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1093\/protein\/gzq022","article-title":"Physico-chemical determinants of soluble intrabody expression in mammalian cell cytoplasm","volume":"23","author":"Kvam","year":"2010","journal-title":"Protein Eng. Des. Sel."},{"key":"10.1016\/j.nbd.2019.104619_bb0400","doi-asserted-by":"crossref","first-page":"4764","DOI":"10.1073\/pnas.071058398","article-title":"Human single-chain Fv intrabodies counteract in situ huntingtin aggregation in cellular models of Huntington's disease","volume":"98","author":"Lecerf","year":"2001","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"590-1","key":"10.1016\/j.nbd.2019.104619_bb0405","first-page":"594","article-title":"Development of a destabilized firefly luciferase enzyme for measurement of gene expression","volume":"29","author":"Leclerc","year":"2000","journal-title":"Biotechniques"},{"key":"10.1016\/j.nbd.2019.104619_bb0410","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.nbd.2010.11.018","article-title":"Proteasomal dysfunction in aging and Huntington disease","volume":"43","author":"Li","year":"2011","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.nbd.2019.104619_bb0415","doi-asserted-by":"crossref","first-page":"34970","DOI":"10.1074\/jbc.273.52.34970","article-title":"Generation of destabilized green fluorescent protein as a transcription reporter","volume":"273","author":"Li","year":"1998","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.nbd.2019.104619_bb0420","doi-asserted-by":"crossref","first-page":"2445","DOI":"10.1093\/hmg\/ddq127","article-title":"Inhibiting the ubiquitin-proteasome system leads to preferential accumulation of toxic N-terminal mutant huntingtin fragments","volume":"19","author":"Li","year":"2010","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.nbd.2019.104619_bb0425","doi-asserted-by":"crossref","first-page":"158","DOI":"10.3389\/fnmol.2019.00158","article-title":"Diverse Misfolded conformational strains and cross-seeding of Misfolded proteins implicated in neurodegenerative diseases","volume":"12","author":"Lim","year":"2019","journal-title":"Front. Mol. Neurosci."},{"key":"10.1016\/j.nbd.2019.104619_bb0430","doi-asserted-by":"crossref","first-page":"8173","DOI":"10.1074\/jbc.M115.641902","article-title":"Co-immunoprecipitation with tau isoform-specific antibodies reveals distinct protein interactions and highlights a putative role for 2N tau in disease","volume":"291","author":"Liu","year":"2016","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.nbd.2019.104619_bb0435","doi-asserted-by":"crossref","first-page":"11213","DOI":"10.1016\/S0021-9258(18)99150-7","article-title":"The C terminus of mouse ornithine decarboxylase confers rapid degradation on dihydrofolate reductase. Support for the pest hypothesis","volume":"266","author":"Loetscher","year":"1991","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.nbd.2019.104619_bb0440","doi-asserted-by":"crossref","first-page":"E3755","DOI":"10.1073\/pnas.1600953113","article-title":"Tau protein is essential for stress-induced brain pathology","volume":"113","author":"Lopes","year":"2016","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.nbd.2019.104619_bb0445","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.jmb.2006.07.027","article-title":"Directed evolution of an anti-prion protein scFv fragment to an affinity of 1 pM and its structural interpretation","volume":"363","author":"Luginb\u00fchl","year":"2006","journal-title":"J. Mol. Biol."},{"key":"10.1016\/j.nbd.2019.104619_bb0450","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.jmb.2007.11.096","article-title":"An scFv intrabody against the nonamyloid component of alpha-synuclein reduces intracellular aggregation and toxicity","volume":"377","author":"Lynch","year":"2008","journal-title":"J. Mol. Biol."},{"key":"10.1016\/j.nbd.2019.104619_bb0455","doi-asserted-by":"crossref","first-page":"17611","DOI":"10.1038\/s41598-018-35464-7","article-title":"Computational affinity maturation of camelid single-domain intrabodies against the nonamyloid component of alpha-synuclein","volume":"8","author":"Mahajan","year":"2018","journal-title":"Sci. Rep."},{"key":"10.1016\/j.nbd.2019.104619_bb0460","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/S0092-8674(00)81369-0","article-title":"Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice","volume":"87","author":"Mangiarini","year":"1996","journal-title":"Cell"},{"key":"10.1016\/j.nbd.2019.104619_bb0465","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/sj.gt.3300346","article-title":"Intrabodies: turning the humoral immune system outside in for intracellular immunization","volume":"4","author":"Marasco","year":"1997","journal-title":"Gene Ther."},{"key":"10.1016\/j.nbd.2019.104619_bb0470","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/S0022-1759(99)00159-3","article-title":"Human anti-HIV-1 tat sFv intrabodies for gene therapy of advanced HIV-1-infection and AIDS","volume":"231","author":"Marasco","year":"1999","journal-title":"J. Immunol. Methods"},{"key":"10.1016\/j.nbd.2019.104619_bb0475","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/j.csbj.2016.07.003","article-title":"Antibodies inside of a cell can change its outside: can intrabodies provide a new therapeutic paradigm?","volume":"14","author":"Marschall","year":"2016","journal-title":"Comput. Struct. Biotechnol. J."},{"key":"10.1016\/j.nbd.2019.104619_bb0480","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1006\/jmbi.1998.1840","article-title":"Expression of an antibody fragment at high levels in the bacterial cytoplasm","volume":"280","author":"Martineau","year":"1998","journal-title":"J. Mol. Biol."},{"key":"10.1016\/j.nbd.2019.104619_bb0485","doi-asserted-by":"crossref","first-page":"647","DOI":"10.3389\/fnins.2017.00647","article-title":"The evidence for the spread and seeding capacities of the mutant Huntingtin protein in in vitro systems and their therapeutic implications","volume":"11","author":"Masnata","year":"2017","journal-title":"Front. Neurosci."},{"key":"10.1016\/j.nbd.2019.104619_bb0490","doi-asserted-by":"crossref","DOI":"10.1177\/1179069518772380","article-title":"Tau: a common denominator and therapeutic target for neurodegenerative disorders","volume":"12","author":"Maxan","year":"2018","journal-title":"J. Exp. Neurosci."},{"key":"10.1016\/j.nbd.2019.104619_bb0495","doi-asserted-by":"crossref","first-page":"2003","DOI":"10.1096\/fj.07-099689","article-title":"Combinational approach of intrabody with enhanced Hsp70 expression addresses multiple pathologies in a fly model of Huntington's disease","volume":"22","author":"McLear","year":"2008","journal-title":"FASEB J."},{"key":"10.1016\/j.nbd.2019.104619_bb0500","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1016\/j.jmb.2007.09.053","article-title":"A protein silencing switch by ligand-induced proteasome-targeting intrabodies","volume":"374","author":"Melchionna","year":"2007","journal-title":"J. Mol. Biol."},{"key":"10.1016\/j.nbd.2019.104619_bb0505","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1002\/cne.10776","article-title":"Time course of early motor and neuropathological anomalies in a knock-in mouse model of Huntington's disease with 140 CAG repeats","volume":"465","author":"Menalled","year":"2003","journal-title":"J. Comp. Neurol."},{"key":"10.1016\/j.nbd.2019.104619_bb0510","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1007\/s13311-013-0193-6","article-title":"Intrabodies as neuroprotective therapeutics","volume":"10","author":"Messer","year":"2013","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.nbd.2019.104619_bb0515","doi-asserted-by":"crossref","first-page":"327","DOI":"10.2165\/00063030-200620060-00002","article-title":"The therapeutic potential of intrabodies in neurologic disorders: focus on Huntington and Parkinson diseases","volume":"20","author":"Messer","year":"2006","journal-title":"Biodrugs"},{"key":"10.1016\/j.nbd.2019.104619_bb0520","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1517\/14712590903176387","article-title":"Developing intrabodies for the therapeutic suppression of neurodegenerative pathology","volume":"9","author":"Messer","year":"2009","journal-title":"Expert. Opin. Biol. Ther."},{"key":"10.1016\/j.nbd.2019.104619_bb0525","series-title":"Gene Therapy of the Central Nervous System : From Bench to Bedside","first-page":"133","article-title":"Gene therapy for CNS diseases using Intrabodies","author":"Miller","year":"2006"},{"key":"10.1016\/j.nbd.2019.104619_bb0530","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1016\/S1525-0016(03)00063-7","article-title":"DNA vaccination against mutant huntingtin ameliorates the HDR6\/2 diabetic phenotype","volume":"7","author":"Miller","year":"2003","journal-title":"Mol. Ther."},{"key":"10.1016\/j.nbd.2019.104619_bb0535","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.nbd.2004.11.003","article-title":"A human single-chain Fv intrabody preferentially targets amino-terminal Huntingtin's fragments in striatal models of Huntington's disease","volume":"19","author":"Miller","year":"2005","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.nbd.2019.104619_bb0540","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.nbd.2004.11.003","article-title":"A human single-chain Fv intrabody preferentially targets amino-terminal huntingtin fragments in striatal models of Huntington's disease","volume":"19","author":"Miller","year":"2005","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.nbd.2019.104619_bb0545","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1128\/CVI.00611-15","article-title":"Adenoviral expression of a Bispecific VHH-based neutralizing agent that targets protective antigen provides prophylactic protection from Anthrax in mice","volume":"23","author":"Moayeri","year":"2016","journal-title":"Clin. Vaccine Immunol."},{"key":"10.1016\/j.nbd.2019.104619_bb0550","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1007\/978-1-4939-7825-0_12","article-title":"Large-brained animal models of Huntington's disease: sheep","volume":"1780","author":"Morton","year":"2018","journal-title":"Methods Mol. Biol."},{"key":"10.1016\/j.nbd.2019.104619_bb0555","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1186\/1750-1326-9-43","article-title":"Alpha-synuclein and tau: teammates in neurodegeneration?","volume":"9","author":"Moussaud","year":"2014","journal-title":"Mol. Neurodegener."},{"key":"10.1016\/j.nbd.2019.104619_bb0560","doi-asserted-by":"crossref","first-page":"7216","DOI":"10.1128\/MCB.19.10.7216","article-title":"ATP-dependent inactivation and sequestration of ornithine decarboxylase by the 26S proteasome are prerequisites for degradation","volume":"19","author":"Murakami","year":"1999","journal-title":"Mol. Cell. Biol."},{"key":"10.1016\/j.nbd.2019.104619_bb0565","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.molbrainres.2003.11.011","article-title":"A single-chain Fv intrabody provides functional protection against the effects of mutant protein in an organotypic slice culture model of Huntington's disease","volume":"121","author":"Murphy","year":"2004","journal-title":"Brain Res. Mol. Brain Res."},{"key":"10.1016\/j.nbd.2019.104619_bb0570","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.vetimm.2008.10.299","article-title":"Camelid immunoglobulins and nanobody technology","volume":"128","author":"Muyldermans","year":"2009","journal-title":"Vet. Immunol. Immunopathol."},{"key":"10.1016\/j.nbd.2019.104619_bb0575","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1038\/s41598-017-01510-z","article-title":"The pathogenic exon 1 HTT protein is produced by incomplete splicing in Huntington's disease patients","volume":"7","author":"Neueder","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.nbd.2019.104619_bb0580","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1093\/brain\/awx052","article-title":"Combined effects of scanning ultrasound and a tau-specific single chain antibody in a tau transgenic mouse model","volume":"140","author":"Nisbet","year":"2017","journal-title":"Brain"},{"key":"10.1016\/j.nbd.2019.104619_bb0585","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1111\/neup.12427","article-title":"Molecular mechanisms of the co-deposition of multiple pathological proteins in neurodegenerative diseases","volume":"38","author":"Nonaka","year":"2018","journal-title":"Neuropathology"},{"key":"10.1016\/j.nbd.2019.104619_bb0590","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1038\/mt.2013.239","article-title":"Adeno-associated virus-mediated delivery of a recombinant single-chain antibody against misfolded superoxide dismutase for treatment of amyotrophic lateral sclerosis","volume":"22","author":"Patel","year":"2014","journal-title":"Mol. Ther."},{"key":"10.1016\/j.nbd.2019.104619_bb0595","doi-asserted-by":"crossref","first-page":"3338","DOI":"10.1523\/JNEUROSCI.0285-07.2007","article-title":"Aggregated alpha-synuclein mediates dopaminergic neurotoxicity in vivo","volume":"27","author":"Periquet","year":"2007","journal-title":"J. Neurosci."},{"key":"10.1016\/j.nbd.2019.104619_bb0600","doi-asserted-by":"crossref","first-page":"1898","DOI":"10.1093\/hmg\/ddu606","article-title":"Alpha-Synuclein modifies mutant huntingtin aggregation and neurotoxicity in Drosophila","volume":"24","author":"Pocas","year":"2015","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.nbd.2019.104619_bb0605","doi-asserted-by":"crossref","first-page":"10","DOI":"10.4061\/2011\/265084","article-title":"The aggregation inhibitor peptide QBP1 as a therapeutic molecule for the Polyglutamine neurodegenerative diseases","volume":"2011","author":"Popiel","year":"2011","journal-title":"J. Amino Acids"},{"key":"10.1016\/j.nbd.2019.104619_bb0610","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1172\/JCI123931","article-title":"Virus-mediated delivery of antibody targeting TAR DNA-binding protein-43 mitigates associated neuropathology","volume":"129","author":"Pozzi","year":"2019","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.nbd.2019.104619_bb0615","doi-asserted-by":"crossref","first-page":"1516","DOI":"10.1056\/NEJM200105173442006","article-title":"Shattuck lecture--neurodegenerative diseases and prions","volume":"344","author":"Prusiner","year":"2001","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.nbd.2019.104619_bb0620","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1111\/jnc.13256","article-title":"Mitochondrial impairment and oxidative stress compromise autophagosomal degradation of alpha-synuclein in oligodendroglial cells","volume":"135","author":"Pukass","year":"2015","journal-title":"J. Neurochem."},{"key":"10.1016\/j.nbd.2019.104619_bb0625","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1523\/JNEUROSCI.1409-03.2004","article-title":"Huntingtin bodies sequester vesicle-associated proteins by a polyproline-dependent interaction","volume":"24","author":"Qin","year":"2004","journal-title":"J. Neurosci."},{"key":"10.1016\/j.nbd.2019.104619_bb0630","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/S0968-0004(96)10031-1","article-title":"PEST sequences and regulation by proteolysis","volume":"21","author":"Rechsteiner","year":"1996","journal-title":"Trends Biochem. Sci."},{"key":"10.1016\/j.nbd.2019.104619_bb0635","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1016\/j.jmb.2011.09.014","article-title":"The rate of polyQ-mediated aggregation is dramatically affected by the number and location of surrounding domains","volume":"413","author":"Robertson","year":"2011","journal-title":"J. Mol. Biol."},{"key":"10.1016\/j.nbd.2019.104619_bb0640","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1093\/hmg\/ddl440","article-title":"The first 17 amino acids of Huntingtin modulate its sub-cellular localization, aggregation and effects on calcium homeostasis","volume":"16","author":"Rockabrand","year":"2007","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.nbd.2019.104619_bb0645","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1126\/science.2876518","article-title":"Amino acid sequences common to rapidly degraded proteins: the PEST hypothesis","volume":"234","author":"Rogers","year":"1986","journal-title":"Science"},{"key":"10.1016\/j.nbd.2019.104619_bb0650","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1038\/nrneurol.2016.5","article-title":"Neurodegenerative disease in 2015: targeting tauopathies for therapeutic translation","volume":"12","author":"Rojas","year":"2016","journal-title":"Nat. Rev. Neurol."},{"key":"10.1016\/j.nbd.2019.104619_bb0655","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1038\/mt.2010.111","article-title":"Abeta-directed single-chain antibody delivery via a serotype-1 AAV vector improves learning behavior and pathology in Alzheimer's disease mice","volume":"18","author":"Ryan","year":"2010","journal-title":"Mol. Ther."},{"key":"10.1016\/j.nbd.2019.104619_bb0660","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.jmb.2011.09.034","article-title":"A disulfide-free single-domain v(l) intrabody with blocking activity towards huntingtin reveals a novel mode of epitope recognition","volume":"414","author":"Schiefner","year":"2011","journal-title":"J Mol Biol."},{"key":"10.1016\/j.nbd.2019.104619_bb0665","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1111\/jnc.12226","article-title":"Oxidative and nitrative alpha-synuclein modifications and proteostatic stress: implications for disease mechanisms and interventions in synucleinopathies","volume":"125","author":"Schildknecht","year":"2013","journal-title":"J. Neurochem."},{"key":"10.1016\/j.nbd.2019.104619_bb0670","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1128\/CVI.00730-15","article-title":"A Tetraspecific VHH-based neutralizing antibody modifies disease outcome in three animal models of Clostridium difficile infection","volume":"23","author":"Schmidt","year":"2016","journal-title":"Clin. Vaccine Immunol."},{"key":"10.1016\/j.nbd.2019.104619_bb0675","doi-asserted-by":"crossref","first-page":"4071","DOI":"10.1073\/pnas.0611693104","article-title":"A phase I clinical trial with monoclonal antibody ch806 targeting transitional state and mutant epidermal growth factor receptors","volume":"104","author":"Scott","year":"2007","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.nbd.2019.104619_bb0680","doi-asserted-by":"crossref","first-page":"6157","DOI":"10.1073\/pnas.95.11.6157","article-title":"Efficient construction of a large nonimmune phage antibody library: the production of high-affinity human single-chain antibodies to protein antigens","volume":"95","author":"Sheets","year":"1998","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.nbd.2019.104619_bb0685","doi-asserted-by":"crossref","first-page":"3855","DOI":"10.1021\/bi0120906","article-title":"Molecular crowding accelerates fibrillization of alpha-synuclein: could an increase in the cytoplasmic protein concentration induce Parkinson's disease?","volume":"41","author":"Shtilerman","year":"2002","journal-title":"Biochemistry"},{"key":"10.1016\/j.nbd.2019.104619_bb0690","series-title":"Nucleocytoplasmic Shuttling of Antigen in Mammalian Cells Conferred by a Soluble Versus Insoluble Single-Chain Antibody Fragment Equipped With Import\/Export Signals","author":"Sibler","year":"2003"},{"key":"10.1016\/j.nbd.2019.104619_bb0695","doi-asserted-by":"crossref","first-page":"2878","DOI":"10.1111\/j.1742-4658.2005.04709.x","article-title":"Extended half-life upon binding of destabilized intrabodies allows specific detection of antigen in mammalian cells","volume":"272","author":"Sibler","year":"2005","journal-title":"FEBS J."},{"key":"10.1016\/j.nbd.2019.104619_bb0700","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1159\/000354491","article-title":"Tau immunotherapy and imaging","volume":"13","author":"Sigurdsson","year":"2014","journal-title":"Neurodegener. Dis."},{"key":"10.1016\/j.nbd.2019.104619_bb0705","first-page":"8","article-title":"Targeted degradation of aberrant tau in frontotemporal dementia patient-derived neuronal cell models","author":"Silva","year":"2019","journal-title":"Elife"},{"key":"10.1016\/j.nbd.2019.104619_bb0710","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1093\/hmg\/ddg169","article-title":"Selective striatal neuronal loss in a YAC128 mouse model of Huntington disease","volume":"12","author":"Slow","year":"2003","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.nbd.2019.104619_bb0715","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1097\/NEN.0b013e3181f530ec","article-title":"Early or late-stage anti-N-terminal Huntingtin intrabody gene therapy reduces pathological features in B6.HDR6\/1 mice","volume":"69","author":"Snyder-Keller","year":"2010","journal-title":"J. Neuropathol. Exp. Neurol."},{"key":"10.1016\/j.nbd.2019.104619_bb0720","doi-asserted-by":"crossref","first-page":"9013","DOI":"10.1523\/JNEUROSCI.2747-08.2008","article-title":"Intrabodies binding the proline-rich domains of mutant huntingtin increase its turnover and reduce neurotoxicity","volume":"28","author":"Southwell","year":"2008","journal-title":"J. Neurosci."},{"key":"10.1016\/j.nbd.2019.104619_bb0725","doi-asserted-by":"crossref","first-page":"13589","DOI":"10.1523\/JNEUROSCI.4286-09.2009","article-title":"Intrabody gene therapy ameliorates motor, cognitive, and neuropathological symptoms in multiple mouse models of Huntington's disease","volume":"29","author":"Southwell","year":"2009","journal-title":"J. Neurosci."},{"key":"10.1016\/j.nbd.2019.104619_bb0730","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0016676","article-title":"Perturbation with intrabodies reveals that calpain cleavage is required for degradation of huntingtin exon 1","volume":"6","author":"Southwell","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.nbd.2019.104619_bb0735","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/s40478-016-0410-8","article-title":"Anti-alpha-synuclein immunotherapy reduces alpha-synuclein propagation in the axon and degeneration in a combined viral vector and transgenic model of synucleinopathy","volume":"5","author":"Spencer","year":"2017","journal-title":"Acta. Neuropathol. Commun."},{"key":"10.1016\/j.nbd.2019.104619_bb0740","doi-asserted-by":"crossref","first-page":"6469","DOI":"10.1073\/pnas.95.11.6469","article-title":"Alpha-Synuclein in filamentous inclusions of Lewy bodies from Parkinson's disease and dementia with lewy bodies","volume":"95","author":"Spillantini","year":"1998","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.nbd.2019.104619_bb0745","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1007\/s00401-017-1786-7","article-title":"Co-occurrence of mixed proteinopathies in late-stage Huntington's disease","volume":"135","author":"St-Amour","year":"2018","journal-title":"Acta Neuropathol."},{"key":"10.1016\/j.nbd.2019.104619_bb0750","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1126\/science.1092194","article-title":"SUMO modification of Huntingtin and Huntington's disease pathology","volume":"304","author":"Steffan","year":"2004","journal-title":"Science"},{"key":"10.1016\/j.nbd.2019.104619_bb0755","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/B978-0-444-63233-3.00011-7","article-title":"The CAG-polyglutamine repeat diseases: a clinical, molecular, genetic, and pathophysiologic nosology","volume":"147","author":"Stoyas","year":"2018","journal-title":"Handb. Clin. Neurol."},{"key":"10.1016\/j.nbd.2019.104619_bb0760","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1038\/mt.2009.174","article-title":"Generating differentially targeted amyloid-beta specific intrabodies as a passive vaccination strategy for Alzheimer's disease","volume":"17","author":"Sudol","year":"2009","journal-title":"Mol. Ther."},{"key":"10.1016\/j.nbd.2019.104619_bb0765","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1042\/BJ20071239","article-title":"Structural elements of the ubiquitin-independent proteasome degron of ornithine decarboxylase","volume":"410","author":"Takeuchi","year":"2008","journal-title":"Biochem. J."},{"key":"10.1016\/j.nbd.2019.104619_bb0770","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1093\/hmg\/ddr507","article-title":"Alpha-Synuclein accumulates in huntingtin inclusions but forms independent filaments and its deficiency attenuates early phenotype in a mouse model of Huntington's disease","volume":"21","author":"Tomas-Zapico","year":"2012","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.nbd.2019.104619_bb0775","doi-asserted-by":"crossref","first-page":"2054","DOI":"10.1016\/j.celrep.2014.05.033","article-title":"Alpha-synuclein immunotherapy blocks uptake and templated propagation of misfolded alpha-synuclein and neurodegeneration","volume":"7","author":"Tran","year":"2014","journal-title":"Cell Rep."},{"key":"10.1016\/j.nbd.2019.104619_bb0780","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1016\/j.toxicon.2010.07.003","article-title":"Camelid single domain antibodies (VHHs) as neuronal cell intrabody binding agents and inhibitors of Clostridium botulinum neurotoxin (BoNT) proteases","volume":"56","author":"Tremblay","year":"2010","journal-title":"Toxicon"},{"key":"10.1016\/j.nbd.2019.104619_bb0785","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/s40478-016-0409-1","article-title":"Combination of alpha-synuclein immunotherapy with anti-inflammatory treatment in a transgenic mouse model of multiple system atrophy","volume":"5","author":"Valera","year":"2017","journal-title":"Acta. Neuropathol. Commun."},{"key":"10.1016\/j.nbd.2019.104619_bb0790","doi-asserted-by":"crossref","first-page":"2689","DOI":"10.1093\/hmg\/11.22.2689","article-title":"Aggregate formation inhibits proteasomal degradation of polyglutamine proteins","volume":"11","author":"Verhoef","year":"2002","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.nbd.2019.104619_bb0795","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1016\/j.bbrc.2005.10.146","article-title":"KDEL-tagged anti-prion intrabodies impair PrP lysosomal degradation and inhibit scrapie infectivity","volume":"338","author":"Vetrugno","year":"2005","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.nbd.2019.104619_bb0800","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1006\/jmbi.2002.5392","article-title":"The intracellular antibody capture technology (IACT): towards a consensus sequence for intracellular antibodies","volume":"317","author":"Visintin","year":"2002","journal-title":"J. Mol. Biol."},{"key":"10.1016\/j.nbd.2019.104619_bb0805","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.mad.2009.11.006","article-title":"Effect of progerin on the accumulation of oxidized proteins in fibroblasts from Hutchinson Gilford progeria patients","volume":"131","author":"Viteri","year":"2010","journal-title":"Mech. Ageing Dev."},{"key":"10.1016\/j.nbd.2019.104619_bb0810","doi-asserted-by":"crossref","first-page":"1907","DOI":"10.1093\/brain\/awv107","article-title":"The role of tau in the pathological process and clinical expression of Huntington's disease","volume":"138","author":"Vuono","year":"2015","journal-title":"Brain"},{"key":"10.1016\/j.nbd.2019.104619_bb0815","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1083\/jcb.200710158","article-title":"Suppression of neuropil aggregates and neurological symptoms by an intracellular antibody implicates the cytoplasmic toxicity of mutant huntingtin","volume":"181","author":"Wang","year":"2008","journal-title":"J. Cell Biol."},{"key":"10.1016\/j.nbd.2019.104619_bb0820","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1159\/000285516","article-title":"Generation of tau aggregates and clearance by autophagy in an inducible cell model of tauopathy","volume":"7","author":"Wang","year":"2010","journal-title":"Neurodegener. Dis."},{"key":"10.1016\/j.nbd.2019.104619_bb0825","doi-asserted-by":"crossref","first-page":"8211","DOI":"10.1523\/JNEUROSCI.1134-18.2018","article-title":"14\u20133-3 Proteins reduce cell-to-cell transfer and propagation of pathogenic \u03b1-synuclein","volume":"38","author":"Wang","year":"2018","journal-title":"J. Neurosci."},{"key":"10.1016\/j.nbd.2019.104619_bb0830","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1016\/j.jmb.2012.01.030","article-title":"Physical chemistry of polyglutamine: intriguing tales of a monotonous sequence","volume":"421","author":"Wetzel","year":"2012","journal-title":"J. Mol. Biol."},{"key":"10.1016\/j.nbd.2019.104619_bb0835","doi-asserted-by":"crossref","first-page":"20","DOI":"10.6064\/2012\/796024","article-title":"The role of tau in neurodegenerative diseases and its potential as a therapeutic target","volume":"2012","author":"Wolfe","year":"2012","journal-title":"Scientifica"},{"key":"10.1016\/j.nbd.2019.104619_bb0840","doi-asserted-by":"crossref","first-page":"11563","DOI":"10.1073\/pnas.0505321102","article-title":"Suppression of Huntington's disease pathology in Drosophila by human single-chain Fv antibodies","volume":"102","author":"Wolfgang","year":"2005","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.nbd.2019.104619_bb0845","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.mcn.2013.01.004","article-title":"Oxidative stress-induced posttranslational modifications of alpha-synuclein: specific modification of alpha-synuclein by 4-hydroxy-2-nonenal increases dopaminergic toxicity","volume":"54","author":"Xiang","year":"2013","journal-title":"Mol. Cell. Neurosci."},{"key":"10.1016\/j.nbd.2019.104619_bb0850","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.1093\/emboj\/cdg158","article-title":"Determinants of proteasome recognition of ornithine decarboxylase, a ubiquitin-independent substrate","volume":"22","author":"Zhang","year":"2003","journal-title":"EMBO J."},{"key":"10.1016\/j.nbd.2019.104619_bb0855","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1016\/j.bbadis.2008.09.001","article-title":"Intrabody and Parkinson's disease","volume":"1792","author":"Zhou","year":"2008","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.nbd.2019.104619_bb0860","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1016\/j.ymthe.2004.08.019","article-title":"A human single-chain Fv intrabody blocks aberrant cellular effects of overexpressed alpha-synuclein","volume":"10","author":"Zhou","year":"2004","journal-title":"Mol. Ther."}],"container-title":["Neurobiology of Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0969996119302943?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0969996119302943?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T05:17:46Z","timestamp":1760851066000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0969996119302943"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2]]},"references-count":172,"alternative-id":["S0969996119302943"],"URL":"https:\/\/doi.org\/10.1016\/j.nbd.2019.104619","relation":{},"ISSN":["0969-9961"],"issn-type":[{"value":"0969-9961","type":"print"}],"subject":[],"published":{"date-parts":[[2020,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Optimizing intracellular antibodies (intrabodies\/nanobodies) to treat neurodegenerative disorders","name":"articletitle","label":"Article Title"},{"value":"Neurobiology of Disease","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.nbd.2019.104619","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"104619"}}